Company: INMB
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001213900-25-033742
Chunk: 39

Company: Inmune Bio, Inc.
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 39
---
 the offering, including Raymond J. Tesi, M.D. (CEO), David Moss (CFO), and Scott Juda, J.D. (Director) paid a combined offering price of $8.445 per share and warrant for total investments of $150,000, 150,000 and 246,297, respectfully, and other third party investors paid $8.32 per share and warrant. The exercise price of the warrants is $9.152, and the term is the earlier of two years from the issuance of the warrants and thirty trading days following the release of top line data in the Company’s phase II Alzheimer’s program, provided that directors and officers of the Company that are subject to a blackout with respect to trading in the Company’s stock will have an additional 60 days from the termination of the blackout date to exercise the warrant. September 2024 Registered Direct Offering During September 2024, the Company entered into securities purchase agreements with investors whereby the Company sold 2,341,260 shares of the Company’s common stock and warrants to purchase an additional 2,341,260 shares of the Company’s common stock in a registered direct offering in exchange for gross proceeds of $13.0 million (net proceeds of approximately $12.0 million). Of this amount, Praetorian Capital Fund LLC purchased 180,800shares and 180,800 warrants with an exercise price of $6.40 in exchange for a total investment of $994,000. Praetorian Capital Fund LLC and related affiliated entities beneficially own more than 5% of our voting securities. Directors and officers that participated in the offering, including Raymond J. Tesi, M.D. (CEO), and David Moss (CFO) paid a combined offering price of $6.50 per share and warrant for total investments of $99,970 and $49,985, respectfully, and other third party investors paid $5.50 per share and warrant. The exercise price of the warrants is $6.40, and are exercisable beginning on March 16, 2025 and will terminate on March 16, 2030 unless accelerated pursuant to the terms of the warrant agreements. Procedures for Approval of Related Party Transactions Related party transactions are subject to the advance review and approval of the audit committee and/or the full Board of Directors, with advice from outside counsel. In its review, the audit committee and/or Board of Directors is provided with full disclosure of the parties involved in the transaction and considers the relationships amongst the parties and